Bosch Health Campus Logo Bosch Health Campus Logo
Home

About

Altered metabolism significantly impacts the efficacy and resistance of cancer therapies. Our re-search focuses on metabolic drug targets, including ADME processes of drugs. Here, we investigate tumour heterogeneity and the role of metabolic cross-talk in the tumour microenvironment for therapy response (e.g. immunotherapy) through various spatial omics technologies in renal cancer as a model for metabolic disease. We aim to unravel the complex of metabolic characteristics and de-velop personalized treatment approaches to address distinct metabolic traits, ultimately enhancing patient outcomes.

Heads

Dr. Elke Schaeffeler
Research Group Leader Metabolism and Cancer Therapy
Head of Molecular Analytics
Tel+49-711-8101 3729
elke.schaeffeler@ikp-stuttgart.de
Go to profile
Prof. Dr. Matthias Schwab
Head of the Institute; Research Group Leader Pharmacogenomics and Digital Health, and of Metabolism and Cancer Therapy
Tel+49-711-8101 3700
matthias.schwab@ikp-stuttgart.de
Go to profile

Team Members

Dr. Regina Bohnert
Bioinformatician, Head of Molecular Analytics
Tel+49-711-8101 2644
regina.bohnert@ikp-stuttgart.de
Go to profile
M. Sc. Hannah Heinrich
Bioinformatician
Tel+49-711-8101 2832
hannah.heinrich@ikp-stuttgart.de
Dr. Florian Büttner
Senior Scientist
Tel+49-711-8101 2091
florian.buettner@ikp-stuttgart.de
Go to profile
Dr. Oliver Burk
Senior Scientist
Tel+49-711-8101 5091
oliver.burk@ikp-stuttgart.de
Go to profile
M.Sc. Mol. Biosci. Lea Vogt
PhD Student
Tel+49 711 8101‐5013
lea.vogt@ikp-stuttgart.de
Theresa Carlucci
PhD Student
Tel+49-711-8101 7787
theresa.carlucci@ikp-stuttgart.de
Jonathan Matsch
PhD Student, RTG 2816
Tel+49 711 8101-2644
Jonathan.Matsch@ikp-stuttgart.de
Laura Achauer
PhD Student, RTG 2816
Laura.Achauer@ikp-stuttgart.de
Carlo Marggraf
MD Student, RTG 2816
Tel+49 711 8101-5649
carlo.marggraf@ikp-stuttgart.de
Moritz Hilgenberg
MD Student, RTG 2816
moritz.hilgenberg@student.uni-tuebingen.de
Laura Kinkelin
Research Assistant / Technician
Tel+49-711-8101 2742
laura.kinkelin@ikp-stuttgart.de
Jennifer Diemer
Research Assistant / Technician
Tel+49-711-8101 5643
jennifer.diemer@ikp-stuttgart.de

Selected publications of the Research Group

  • Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui C-H, Stein CM, Klein TE, Spahn C, Kwon S, Hartono JL, Boer NK de, Ahmad T, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. Clin Pharmacol Ther. 4(119):916–927, 2026. doi: 10.1002/cpt.70209.
  • Dusek J, Mejdrová I, Dohnalová K, Smutny T, Chalupsky K, Krutakova M, Skoda J, Rashidian A, Pavkova I, Škach K, Hricová J, Chocholouskova M, Smutna L, Kamaraj R, Hroch M, Leníček M, Mičuda S, Pijnenburg D, van Beuningen R, Holčapek M, Vítek L, Ingelman-Sundberg M, Burk O, Kronenberger T, Nencka R, Pavek P. The hypolipidemic effect of MI-883, the combined CAR agonist/ PXR antagonist, in diet-induced hypercholesterolemia model. Nat Commun. 1(16):1418, 2025. doi: 10.1038/s41467-025-56642-y.
  • Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Büttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, van Allen E, Choueiri TK, Braun DA, Shukla SA. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nat Cancer. 2(6):372–384, 2025. doi: 10.1038/s43018-024-00896-w.
  • Klein K, Burk O, Tremmel R, Buettner FA, Kaestle L, Schroth W, Muerdter TE, Eccles D, Schmidt A-C, Nieß H, Zanger UM, Schwab M, Lauschke VM. Transcription factors of the Nuclear Factor I (NFI) family control hepatocyte differentiation and cytochrome P450 activity in human liver. Pharmacol Res(221):107998, 2025. doi: 10.1016/j.phrs.2025.107998.
  • Maillard M, Nishii R, Vu HS, Bhattarai KR, Yang W, Li J, Hofmann U, Savic D, Bhatia S, Schwab M, Ni M, Yang JJ. The NUDIX hydrolase NUDT5 regulates thiopurine metabolism and cytotoxicity. J Clin Invest. 14(135, 2025. doi: 10.1172/JCI190443.
  • Menig-Benzig L-S, Stühler V, Mazzola P, Heinrich H, Hofmann U, Widmann N, Bohnert R, Neef SK, Sauter-Meyerhoff C, Schmees C, Fuhr A, Klumpp V, Rausch S, Gürgen D, Mürdter TE, Winter S, Büttner FA, Kruck S, Choffart A, Martins AF, Hennenlotter J, Barcena ML, Vakhrusheva O, Bahlinger V, Fend F, Tsaur I, Bedke J, Schwab M, Schaeffeler E. Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCC. Pharmacol Res(222):108057, 2025. doi: 10.1016/j.phrs.2025.108057.
  • Mürdter TE, Schroth W, Goetz MP, Tremmel R, Igel S, Schaeffeler E, Jäger S, Loibl S, Gerteis A, Pfaff L, Bechtner C, Wrobel D, Bernhöft I, Fischer I, Meisner C, Block M, Brauch H, Schwab M. Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clin Cancer Res. 23(31):4903–4911, 2025. doi: 10.1158/1078-0432.CCR-25-2103.
  • Tremmel R, Hübschmann D, Schaeffeler E, Pirmann S, Fröhling S, Schwab M. Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes. Pharmacol Rev. 1(77):100014, 2025. doi: 10.1124/pharmrev.124.001049.
  • Junk SV, Schaeffeler E, Zimmermann M, Möricke A, Beier R, Schütte P, Fedders B, Alten J, Hinze L, Klein N, Kulozik A, Muckenthaler MU, Koehler R, Borkhardt A, Vijayakrishnan J, Ellinghaus D, Forster M, Franke A, Wintering A, Kratz CP, Schrappe M, Schwab M, Houlston RS, Cario G, Stanulla M. Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group. : CR. 1(42):21, 2023. doi: 10.1186/s13046-022-02585-x.
  • Nies AT, König J, Leuthold P, Damme K, Winter S, Haag M, Masuda S, Kruck S, Daniel H, Spanier B, Fromm MF, Bedke J, Inui K-I, Schwab M, Schaeffeler E. Novel drug transporter substrates identification: An innovative approach based on metabolomic profiling, in silico ligand screening and biological validation. Pharmacol Res(196):106941, 2023. doi: 10.1016/j.phrs.2023.106941.
  • Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, Schaeffeler E. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Genome Med. 1(14):105, 2022. doi: 10.1186/s13073-022-01105-y.
  • Reustle A, Menig L-S, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M, Schaeffeler E. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clin Transl Med. 6(12):e883, 2022. doi: 10.1002/ctm2.883.